CJC-1295 vs Matrixyl
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Matrixyl is the most widely used collagen-stimulating cosmetic peptide. As a matrikine — a fragment of type I procollagen — it signals skin cells to synthesize new collagen, elastin, and fibronectin, reducing wrinkle depth and improving skin firmness and elasticity.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 100 mcg
- 3–8% concentration
- Frequency
- Once daily, before bed
- Once or twice daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Stimulates collagen I, III, and IV synthesis
- Increases fibronectin and glycosaminoglycan production
- Reduces wrinkle depth and length by 27–68% (studies)
- Improves skin firmness and elasticity
- Reduces dark circles and undereye bags
- Synergistic with retinol, vitamin C, and growth factors
- Suitable for all skin types including sensitive
- Well-studied with published clinical data
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Exceptional safety profile
- Non-irritating, suitable for sensitive skin
- No known adverse effects at cosmetic concentrations
- Stacks With
- —
- —